These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 26928940)

  • 1. Association Between Preadmission Functional Status and Use and Effectiveness of Secondary Prevention Medications in Elderly Survivors of Acute Myocardial Infarction.
    Chrischilles EA; Schneider KM; Schroeder MC; Letuchy E; Wallace RB; Robinson JG; Brooks JM
    J Am Geriatr Soc; 2016 Mar; 64(3):526-35. PubMed ID: 26928940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secondary Prevention Medication Use After Myocardial Infarction in U.S. Nursing Home Residents.
    Zullo AR; Sharmin S; Lee Y; Daiello LA; Shah NR; John Boscardin W; Dore DD; Lee SJ; Steinman MA
    J Am Geriatr Soc; 2017 Nov; 65(11):2397-2404. PubMed ID: 29044457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence Tradeoff to Multiple Preventive Therapies and All-Cause Mortality After Acute Myocardial Infarction.
    Korhonen MJ; Robinson JG; Annis IE; Hickson RP; Bell JS; Hartikainen J; Fang G
    J Am Coll Cardiol; 2017 Sep; 70(13):1543-1554. PubMed ID: 28935030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarction.
    Shore S; Jones PG; Maddox TM; Bradley SM; Stolker JM; Arnold SV; Parashar S; Peterson P; Bhatt DL; Spertus J; Ho PM
    Heart; 2015 May; 101(10):800-7. PubMed ID: 25801001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of in-hospital cardiac rehabilitation program on medication adherence and clinical outcomes in patients with acute myocardial infarction in the Lazio region of Italy.
    Soldati S; Di Martino M; Rosa AC; Fusco D; Davoli M; Mureddu GF
    BMC Cardiovasc Disord; 2021 Sep; 21(1):466. PubMed ID: 34565326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guideline-Based Medications for Older Adults Discharged after Percutaneous Coronary Intervention in a Suburban City of Japan: A Cohort Study Using Claims Data.
    Shimada K; Hamada S; Sawano M; Yamamoto H; Yoshie S; Iijima K; Miyata H
    Tohoku J Exp Med; 2020 Oct; 252(2):143-152. PubMed ID: 33028759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decade-Long Trends (2001 to 2011) in the Use of Evidence-Based Medical Therapies at the Time of Hospital Discharge for Patients Surviving Acute Myocardial Infarction.
    Makam RC; Erskine N; McManus DD; Lessard D; Gore JM; Yarzebski J; Goldberg RJ
    Am J Cardiol; 2016 Dec; 118(12):1792-1797. PubMed ID: 27743577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of exposure to evidence-based pharmacotherapy on outcomes after acute myocardial infarction in older adults.
    Zuckerman IH; Yin X; Rattinger GB; Gottlieb SS; Simoni-Wastila L; Pierce SA; Huang TY; Shenolikar R; Stuart B
    J Am Geriatr Soc; 2012 Oct; 60(10):1854-61. PubMed ID: 23003000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond medication prescription as performance measures: optimal secondary prevention medication dosing after acute myocardial infarction.
    Arnold SV; Spertus JA; Masoudi FA; Daugherty SL; Maddox TM; Li Y; Dodson JA; Chan PS
    J Am Coll Cardiol; 2013 Nov; 62(19):1791-801. PubMed ID: 23973701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medication use in long-term survivors from the MONICA/KORA Myocardial Infarction Registry.
    Amann U; Kirchberger I; Heier M; Thilo C; Kuch B; Meisinger C
    Eur J Intern Med; 2018 Jan; 47():62-68. PubMed ID: 28826823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Racial/Ethnic and gender gaps in the use of and adherence to evidence-based preventive therapies among elderly Medicare Part D beneficiaries after acute myocardial infarction.
    Lauffenburger JC; Robinson JG; Oramasionwu C; Fang G
    Circulation; 2014 Feb; 129(7):754-63. PubMed ID: 24326988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of a P2Y12 Inhibitor Copayment Reduction Intervention With Persistence and Adherence With Other Secondary Prevention Medications: A Post Hoc Analysis of the ARTEMIS Cluster-Randomized Clinical Trial.
    Fanaroff AC; Peterson ED; Kaltenbach LA; Cannon CP; Choudhry NK; Henry TD; Anstrom KJ; Cohen DJ; Fonseca E; Khan ND; Fonarow GC; Wang TY
    JAMA Cardiol; 2020 Jan; 5(1):38-46. PubMed ID: 31721978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Effectiveness of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in Older Nursing Home Residents After Myocardial Infarction: A Retrospective Cohort Study.
    Zullo AR; Riester MR; Erqou S; Wu WC; Rudolph JL; Steinman MA
    Drugs Aging; 2020 Oct; 37(10):755-766. PubMed ID: 32808250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal secondary prevention medication use in acute myocardial infarction patients with nonobstructive coronary artery disease is modified by management strategy: insights from the TRIUMPH Registry.
    Pitts R; Daugherty SL; Tang F; Jones P; Ho PM; Tsai TT; Spertus J; Maddox TM
    Clin Cardiol; 2017 Jun; 40(6):347-355. PubMed ID: 28387960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction.
    Fang G; Annis IE; Farley JF; Mahendraratnam N; Hickson RP; Stürmer T; Robinson JG
    Pharmacotherapy; 2018 Jan; 38(1):29-41. PubMed ID: 29059475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Quality of Prescription for ST-Segment Elevation Myocardial Infarction (STEMI) Patients: A Real World 1-Year Follow-Up Study.
    Bruggmann C; Iglesias JF; Gex-Fabry M; Fesselet R; Vogt P; Sadeghipour F; Voirol P
    Am J Cardiovasc Drugs; 2020 Feb; 20(1):105-115. PubMed ID: 31300969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of secondary prevention medications in metropolitan and non-metropolitan areas: an analysis of 41 925 myocardial infarctions in Australia.
    Livori AC; Ademi Z; Ilomäki J; Pol D; Morton JI; Bell JS
    Eur J Prev Cardiol; 2024 Mar; 31(5):580-588. PubMed ID: 37987181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence with secondary prevention medications after acute myocardial infarction: Insights from the TRANSLATE-ACS study.
    Mathews R; Wang TY; Honeycutt E; Henry TD; Zettler M; Chang M; Fonarow GC; Peterson ED;
    Am Heart J; 2015 Jul; 170(1):62-9. PubMed ID: 26093865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disability, race/ethnicity, and medication adherence among Medicare myocardial infarction survivors.
    Zhang Y; Baik SH; Chang CC; Kaplan CM; Lave JR
    Am Heart J; 2012 Sep; 164(3):425-433.e4. PubMed ID: 22980311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence to agents acting on the renin-angiotensin system in secondary prevention of non-fatal myocardial infarction: a self-controlled case-series study.
    Ortolani P; Di Bartolomeo S; Marino M; Vagnarelli F; Guastaroba P; Rapezzi C; De Palma R
    Eur Heart J Cardiovasc Pharmacother; 2015 Oct; 1(4):254-9. PubMed ID: 27532449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.